文献速递儿科与产科急症重症综合管理与镇静镇痛

奥替尼啶或无菌水清洁与NICU新生儿迟发型脓毒症:一项随机临床试验

Octenidine or Sterile Water Cleansing and Late-Onset Sepsis in Neonates in the NICU: A Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2026-07-01
一句话结论在NICU新生儿中,每日用0.1%奥替尼啶湿巾全身清洁与无菌水相比,未降低迟发型脓毒症发生率(14.7% vs 12.9%,RR 1.10)。

这项单中心、开放标签、平行组随机临床试验在印度一家三级医院的II级和III级NICU开展,纳入出生48小时内入住NICU、无早发型脓毒症或原有皮肤病变、且72小时内未出院的新生儿,随机接受每日一次0.1%奥替尼啶湿巾或无菌水纱布全身清洁。次要结局包括7天和14天迟发型脓毒症、全因死亡率、NICU住院时长及皮肤不良反应组间相似。结论提示感染预防策略应聚焦多模式干预,而非仅依赖皮肤清洁。

要点

  • 次要结局:7天LOS 9.0% vs 8.7%,14天LOS 5.6% vs 4.2%,全因死亡率4.5% vs 1.9%,NICU住院中位天数11.0 vs 10.0,组间相似。
  • 皮肤不良反应:奥替尼啶组5.6%(15例)vs 无菌水组6.1%(16例),RR 1.10(95%CI 0.55-2.10)。
  • 适用人群:出生48小时内入住NICU、无早发型脓毒症或原有皮肤病变、72小时内未出院的新生儿;不适用于早发型脓毒症或已有皮肤病变者。

适用人群与场景

  • 纳入:出生48小时内入住NICU的新生儿,无早发型脓毒症或原有皮肤病变,且72小时内未从NICU出院。
  • 排除:早发型脓毒症、原有皮肤病变、72小时内出院或转出NICU者。
  • 场景:印度一家三级医院的II级和III级NICU,单中心。

诊断标准与关键阈值

  • 迟发型脓毒症(LOS)定义:出生72小时后至28天生命期内发生的脓毒症,所有病例由2名设盲新生儿科医师独立裁定。
  • 皮肤清洁方案:每日一次全身清洁,使用0.1%奥替尼啶二盐酸盐抗菌湿巾或无菌水纱布,上下半身分开使用湿巾或纱布,生殖器区域最后清洁,涂抹后不冲洗以保留残留抗菌活性。
  • 皮肤状况每日使用新生儿皮肤状况评分(Neonatal Skin Condition Score)评估。

处置流程与药物剂量

  • 第一步:评估新生儿是否符合纳入标准(出生48小时内入住NICU、无早发型脓毒症、无原有皮肤病变、预计72小时内不出院)。
  • 第二步:随机分配至每日一次全身清洁,使用0.1%奥替尼啶二盐酸盐抗菌湿巾或无菌水纱布,直至出院、转院或死亡。
  • 第三步:清洁时上下半身分开使用湿巾或纱布,生殖器区域最后清洁,涂抹后不冲洗。
  • 第四步:每日使用新生儿皮肤状况评分评估皮肤状况,并监测迟发型脓毒症发生。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:单中心、开放标签、平行组随机临床试验;样本量530例(意向性分析),来自印度一家三级医院II级和III级NICU;纳入出生48小时内入住NICU、无早发型脓毒症或原有皮肤病变、72小时内未出院的新生儿。
  • 干预与对照:每日一次全身清洁,0.1%奥替尼啶二盐酸盐抗菌湿巾 vs 无菌水纱布,直至出院、转院或死亡。
  • 关键次要终点:7天LOS 9.0%(24例)vs 8.7%(23例);14天LOS 5.6%(15例)vs 4.2%(11例);全因死亡率4.5%(12例)vs 1.9%(5例);NICU住院中位天数11.0(IQR 6.0-21.0)vs 10.0(IQR 6.0-19.0);皮肤不良反应5.6%(15例)vs 6.1%(16例),RR 1.10(95%CI 0.55-2.10)。

证据类型、等级与局限

  • 证据类型:随机临床试验(RCT)。
  • 证据等级或推荐强度:原文未提及。
  • 局限:单中心、开放标签、样本量530例,可能限制普遍性;原文未提及盲法对干预实施的影响。

对床旁实践的改变

  • 每日使用0.1%奥替尼啶湿巾进行全身皮肤清洁不应被视为降低NICU新生儿迟发型脓毒症发生的有效单一措施,与无菌水相比无额外获益。
  • 感染预防策略应聚焦多模式干预,而非仅依赖皮肤清洁。
  • 适用人群为出生48小时内入住NICU、无早发型脓毒症或原有皮肤病变、72小时内未出院的新生儿;不适用于早发型脓毒症或已有皮肤病变者。
  • 常见陷阱:不能将本研究的阴性结果外推至其他消毒剂或不同清洁频率,也不能据此认为皮肤清洁在所有NICU人群中无效。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: While skin cleansing with octenidine has shown promise in preventing health care infections, its effectiveness for preventing late-onset sepsis in neonates is unproven.

OBJECTIVE: To compare the incidence rates of late-onset sepsis (LOS) in neonates admitted to the neonatal intensive care unit (NICU) who were cleansed daily with octenidine wipes vs those cleansed with sterile water.

DESIGN, SETTING, AND PARTICIPANTS: This single-center, open-label, parallel-group randomized clinical trial was conducted in the level II and level III NICUs of a tertiary care hospital in India between September 1, 2023, and August 31, 2025. All neonates admitted to the NICU within 48 hours of birth without early-onset sepsis or preexisting skin lesions and not discharged from the NICU before 72 hours were included.

INTERVENTION: Neonates were assessed and randomly assigned to receive once-daily full-body cleansing with either 0.1% octenidine dihydrochloride antimicrobial wipes or sterile water applied with sterile gauze until discharge, transfer to another facility, or death. Separate wipes or gauze were used for the upper and lower body, with genital cleansing performed last. No rinsing was performed after application to allow residual antimicrobial activity. Skin condition was assessed daily using the Neonatal Skin Condition Score.

MAIN OUTCOMES AND MEASURES: The primary outcome was LOS rates (occurring >72 hours after birth through 28 days of life) among neonates cleansed with octenidine wipes vs with sterile water until discharge or transfer to the maternal bedside, assessed using relative risk (RR). Time to LOS was compared using the hazard ratio (HR). All cases were independently adjudicated by 2 blinded neonatologists. Secondary outcomes included LOS at 7 and 14 days, all-cause mortality, length of NICU stay, and adverse skin reactions.

RESULTS: Of 530 neonates eligible for intention-to-treat analysis (299 males [56.4%]; median gestational age, 35.0 weeks [IQR, 32.0-37.0 weeks]), LOS occurred in 39 of 266 (14.7%) in the octenidine group and 34 of 264 (12.9%) in the sterile water group (RR, 1.10; 95% CI, 0.75-1.70; P = .60). Time to LOS was similar between groups (HR, 1.11; 95% CI, 0.71-1.78; P = .63). Secondary outcomes for the octenidine vs sterile water interventions were similar, including LOS by 7 days (24 neonates [9.0%] vs 23 [8.7%]) and 14 days (15 [5.6%] vs 11 [4.2%]), all-cause mortality (12 [4.5%] vs 5 [1.9%]), and length of NICU stay in days (median, 11.0 [IQR, 6.0-21.0] vs 10.0 [IQR, 6.0-19.0]). Adverse skin reactions occurred in 15 neonates (5.6%) in the octenidine group and 16 (6.1%) in the sterile water group (RR, 1.10; 95% CI, 0.55-2.10).

CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, daily skin cleansing with octenidine wipes showed no evidence of reducing the incidence of LOS in NICU neonates compared with sterile water, suggesting that infection prevention strategies should focus on multimodal interventions rather than relying solely on skin cleansing.

TRIAL REGISTRATION: CTRI Identifier: CTRI/2023/08/056562.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Udavant S, Patnaik S, Lalwani S, et al. Octenidine or Sterile Water Cleansing and Late-Onset Sepsis in Neonates in the NICU: A Randomized Clinical Trial. JAMA Netw Open. 2026. PMID: 42455570. doi:10.1001/jamanetworkopen.2026.23096

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。